Tianjin Huajin Pharmaceutical Co. Ltd.

This study investigates whether there are differences in the extent and rate of absorption between the test formulation zopiclone capsules (Tianjin Huajin Pharmaceutical Co., Ltd., specification: 7.5 mg) and the reference formulation zopiclone tablets (trade name: Imovane®, Sanofi-Aventis France, specification: 7.5 mg) administered orally in healthy participants on an empty stomach, evaluates the bioequivalence of the test and reference formulations when administered on an empty stomach, and observes the safety of the test and reference formulations in healthy participants.

This study investigates whether there are differences in the absorption rate and extent between the test formulation zopiclone capsules (Tianjin Huajin Pharmaceutical Co., Ltd., specification: 7.5 mg) and the reference formulation zopiclone tablets (trade name: Imovane®, Sanofi-Aventis France, specification: 7.5 mg) administered orally once orally in fasting and postprandial states in healthy trial participants. It also aims to evaluate the bioequivalence trends of the test and reference formulations under fasting and postprandial administration, provide a basis for formal trials, and observe the safety of the test and reference formulations in healthy trial participants.

Primary study objective: To study the pharmacokinetics of the test preparation, Miasartan Potassium Tablets, and the reference preparation, Miasartan Potassium Tablets (trade name: Edabi®; specification: 40 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary study objective: To evaluate the safety of the test preparation, Miasartan Potassium Tablets (specification: 40 mg) and the reference preparation, Edabi® (specification: 40 mg) in healthy subjects.